Omeros shows excellent cash conversion and a perfect 4-quarter earnings beat streak, but a weak Piotroski score, a steep drawdown, and heavy bearish options positioning reflect the binary risk inherent to a speculative biotech name.
Thesis pillars
- Excellent Cash Conversion→Stable
- Momentum Distribution Warning→Stable
- Speculative Binary Biotech Risk→Stable
- +2 more pillars — see the Why tab for full reasoning
Omeros Corporation (OMER) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 26%; Elevated put/call ratio: 4.21; Below long-term trend.
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for... Read more
Sell if holding. Engine safety override at $10.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 26%; Elevated put/call ratio: 4.21; Below long-term trend. Chart setup: RSI 56 mid-range, Bollinger mid-band. Score 5.9/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-07-08Recent Developments — Omeros Corporation
Latest news
- NEWS Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session — benzinga Jun 29, 2026 neutral
Generated 2026-07-08T23:03:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductYARTEMLEA10-K Item 1A: 'YARTEMLEA is our only commercialized product and was approved by FDA for commercial sale in the United States in December 2025.'
- HIGHSupplierLonza10-K Item 1: 'we entered into a master services agreement with Lonza Biologics Tuas Pte. Ltd. ("Lonza") for the commercial production of YARTEMLEA'
- HIGHSupplierVetter10-K Item 1: 'Vetter has agreed to aseptically fill YARTEMLEA in vials for clinical or commercial use'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Volatile — 8.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 26%; Elevated put/call ratio: 4.21; Below long-term trend. Chart setup: RSI 56 mid-range, Bollinger mid-band. Prior stop was $9.52. Score 5.9/10, moderate confidence.
Take-profit target: $10.61 (+3.6% upside). Prior stop was $9.52. Stop-loss: $9.52.
Concentration risk — Product: YARTEMLEA; Concentration risk — Supplier: Lonza; DATA_ISSUE: analyst_target_implausible (raw $33.00 vs price $10.24 — ratio 3.2×). Rejected, falling back to technical TP..
Omeros Corporation trades at a P/E of 9.1 (forward -66.7). TrendMatrix value score: 9.2/10. Verdict: Sell.
10 analysts cover OMER with a consensus score of 4.0/5. Average price target: $33.
What does Omeros Corporation do?Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule...
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.